Lymphoma Hub

During the Lymphoma Hub Steering Committee Meeting on April 20, 2026, key opinion leaders met to discuss results from the long-term follow-up of the phase III SEQUOIA trial (NCT03336333) evaluating zanubrutinib in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The discussion was chaired by Jacob Soumerai and featured Gilles Salles, Ulrich Jäge...

During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2025, Stockholm, SE, the Lymphoma Hub spoke with Stephen Schuster, University of Pennsylvania, Philadelphia, US. We asked, What are the key findings from the phase I ANTLER trial in R/R B-cell NHL? This educational resource is independently supported by Caribou Biosciences. All content is developed by SES in collaboration...

During the American Society of Clinical Oncology Annual Meeting, May 19 – June 2, 2026, Chicago, US, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount Sinai, New York, US. Hosted on Acast. See acast.com/privacy for more information.

During the 31st European Hematology Association (EHA) Congress, June 11–14, 2025, Stockholm, SE, the Lymphoma Hub spoke with Dr. Talha Munir, Leeds Teaching Hospital, Leeds, UK. We asked, What are the most recent findings from the phase I NX-5948-301 trial evaluating bexobrutideg in chronic lymphocytic leukemia (CLL)? This educational resource is independently supported by Nurix. All content was d...

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount Sinai, New York, US. Brody discussed the key highlights in lymphoma and chronic lymphocytic leukemia (CLL) from the meeting. Brody highlights several presentations on approved and nove...

During the  67th American Society of Hematology (ASH) Annual Meeting and Exposition , December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with  Alexey Danilov , City of Hope Comprehensive Cancer Center, Duarte, US. We asked, What are the latest updates from the phase I  NX-5948-301  trial of  bexobrutideg...

The Lymphoma Hub was pleased to speak to Susan O’Brien, Chao Family Comprehensive Cancer Center, University of California, Irvine, US. We asked, What do the clinical data tell us about fixed-duration ibrutinib + venetoclax for patients with chronic lymphocytic leukemia (CLL) ? This educational resource is independently supported by Johnson & Johnson. All content was developed by SES in collabo...

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Lorenzo Falchi, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What do the primary results from the EPCORE FL-1 trial tell us about epcoritamab + R2 vs R2 alone in patients with R/R FL? In this interview, Falchi highlights...

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Haifaa Abdulhaq, University of California, San Francisco, US. We asked, What do the 3-year follow-up results from the STARGLO trial tell us about glofitamab (Glofit) + gemcitabine + oxaliplatin (GemOx) treatment in patients with relapsed/re...

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Adelba Torres, Hospital Auxilio Mutuo, San Juan, PR. We asked, What does the latest analysis of the EPCORE NHL-6 trial tell us about the efficacy and safety of bispecific antibodies in an ethnically and racially diverse patient population?...

During the Lymphoma Hub Steering Committee Meeting on October 6, 2025, key opinion leaders met to discuss the results from the phase III STARGLO trial (NCT04408638) of glofitamab (Glofit) + gemcitabine + oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The discussion was preceded by a presentation by Gareth Gregory, chaire...

The Lymphoma Hub was pleased to speak to Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, what factors influence Bruton’s tyrosine kinase inhibitor (BTKi) + B-cell lymphoma 2 inhibitor (BCL-2i) treatment selection for patients with chronic lymphocytic leukemia (CLL)? This educational resource is independently supported by Johnson & Johnson. All content was deve...

The Lymphoma Hub was pleased to speak to Charles Herbaux, University of Montpellier, FR. Herbaux discussed the latest updates from the phase III STARGLO trial (NCT04408638), with a focus on second-line (2L) and third-line+ (3L+) data. This educational resource is independently supported by Roche. All content is developed by SES in collaboration with an expert steering committee. Funders are allowe...

During the 18th International Conference on Malignant Lymphoma (ICML), June 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Customizing therapy for mantle cell lymphoma (MCL). The symposium concluded with a Q&A session, where the panelists, Gilles Salles, Julie Vose, Wojciech Jurczak, and Michael Wang, answered questions from the live audience. This educatio...

During the 18th International Conference on Malignant Lymphoma (ICML), June 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Customizing therapy for mantle cell lymphoma (MCL). Here, we share a presentation by Michael Wang, MD Anderson Cancer Center, Houston, US, discussing current therapies for MCL and their combinations. Wang provided an overview of current the...

During the 18th International Conference on Malignant Lymphoma (ICML), June 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Customizing therapy for mantle cell lymphoma (MCL). Here, we share a case-based presentation and panel discussion led by Wojciech Jurczak, Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, PL, on sequencing therapies a...

During the 18th International Conference on Malignant Lymphoma (ICML), Jun 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Customizing therapy for mantle cell lymphoma (MCL). Here, we share a presentation by Julie Vose, University of Nebraska Medical Center, Omaha, US, discussing unmet needs in the treatment of MCL.    Vose provides an overview of the...

During the Lymphoma Hub Steering Committee meeting, Grzegorz Nowakowski, the Mayo Clinic, Rochester, US, chaired a discussion on anti-CD19 monoclonal antibodies for the treatment of DLBCL. This discussion also featured Gilles Salles, Sonali Smith, Ulrich Jäger, Catherine Thieblemont, Michael Dickinson, Francesc Bosch, Miles Prince, and Marek Trněný. Prior to the discussion, Nowakowski presented an...

During the Lymphoma Hub Steering Committee Meeting, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, chaired a discussion on cereblon E3 ligase modulators (CELMoDs) for the treatment of non-Hodgkin lymphoma. This discussion also featured Grzegorz Nowakowski, Sonali Smith, Ulrich Jäger, Catherine Thieblemont, Michael Dickinson, Francesc Bosch, Miles Prince, and Marek Trněný. Pri...

During the 18th International Conference on Malignant Lymphoma (ICML), Jun 17–21, 2025, Lugano, CH, the Lymphoma Hub was pleased to speak with Juan Pablo Alderuccio, University of Miami, Florida, US. We asked, What do the initial results from the LOTIS-7 (NCT04970901) trial suggest for loncastuximab tesirine plus glofitamab in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)?  ...

During the 18th International Conference on Malignant Lymphomas (ICML), Jun 17–21, 2025, Lugano, CH, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount Sinai, New York, US. We asked about the clinical significance of the long-term results from the  EPCORE NHL-2  ( NCT04663347 ) trial, which evaluated  epcoritamab  (epcor) in combi...

This educational resource is independently supported by Roche. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.  During the 30th European Hematology Association (EHA) Congress, the Lymphoma Hub was pleased to speak to Gareth Gregory, Monash University, Melbourne, AU. We asked about the latest...

This educational resource is independently supported by AbbVie. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.  During the 30th European Hematology Association (EHA) Congress, the Lymphoma Hub was pleased to speak to Marek Trněný, Charles University, Prague, CZ. We asked, How effective is ep...

The Lymphoma Hub was pleased to speak to Grzegorz S. Nowakowski, Mayo Clinic, Rochester, US, who discussed the real-world experience of tafasitamab and lenalidomide for the treatment of relapsed/refractory diffuse large B-cell lymphoma.    This educational resource is independently supported by Incyte. All content is developed by SES in collaboration with an expert steering committee; fu...

This educational resource is independently supported by Incyte. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.     Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, discusses the evolving treatment landscape for relapsed/refractory diffuse large B-cell lymphoma, focus...